益普索：2025年围手术期战略转向：驾驭早期癌症免疫治疗新前沿研究报告（英文版）

The history of oncology is a story of powerful advances. For decades, adjuvant (postsurgical) treatment relied on the one-size-fits-all application of chemotherapy and radiation. The first revolution came with targeted therapies in diseases like breast cancer (HER2-targeted agents). The current trend is to develop approved immunotherapies for line extensions in these early-stage, curative-intent settings. What began with approvals in high-risk melanoma has now become a clear industrywide tren